ATE344261T1 - Cyclische n-aroylamine als orexinrezeptorantagonisten - Google Patents
Cyclische n-aroylamine als orexinrezeptorantagonistenInfo
- Publication number
- ATE344261T1 ATE344261T1 AT03797310T AT03797310T ATE344261T1 AT E344261 T1 ATE344261 T1 AT E344261T1 AT 03797310 T AT03797310 T AT 03797310T AT 03797310 T AT03797310 T AT 03797310T AT E344261 T1 ATE344261 T1 AT E344261T1
- Authority
- AT
- Austria
- Prior art keywords
- aroylamins
- cyclic
- receptor antagonists
- orexin receptor
- orexin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0221690A GB0221690D0 (en) | 2002-09-18 | 2002-09-18 | Compounds |
GB0221691A GB0221691D0 (en) | 2002-09-18 | 2002-09-18 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE344261T1 true ATE344261T1 (de) | 2006-11-15 |
Family
ID=32031882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03797310T ATE344261T1 (de) | 2002-09-18 | 2003-09-17 | Cyclische n-aroylamine als orexinrezeptorantagonisten |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060040937A1 (de) |
EP (1) | EP1539747B1 (de) |
JP (1) | JP2006504695A (de) |
AT (1) | ATE344261T1 (de) |
AU (1) | AU2003262516A1 (de) |
DE (1) | DE60309481T2 (de) |
ES (1) | ES2273083T3 (de) |
WO (1) | WO2004026866A1 (de) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432270B2 (en) * | 2001-05-05 | 2008-10-07 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
US20040192673A1 (en) * | 2001-05-05 | 2004-09-30 | Pascale Gaillard | N-aroyl cyclic amine derivatives as orexin receptor antagonists |
GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
DE60212968T2 (de) * | 2001-06-28 | 2007-02-01 | Smithkline Beecham P.L.C., Brentford | N-aroyl-(cyclisches amin)-derivate als orexinrezeptor antagonisten |
GB0127145D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
EP1751111B1 (de) | 2004-03-01 | 2014-12-31 | Actelion Pharmaceuticals Ltd. | Substituierte 1,2,3,4-tetrahydroisochinolinderivate |
EP2049110B1 (de) | 2006-07-14 | 2014-08-20 | Merck Sharp & Dohme Corp. | Verbrückte diazepanorexin-rezeptorantagonisten |
DE602007012910D1 (de) * | 2006-08-15 | 2011-04-14 | Actelion Pharmaceuticals Ltd | Azetidinverbindungen als orexin-rezeptor-antagonisten |
CA2662612A1 (en) * | 2006-09-29 | 2008-04-03 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.1.0]hexane derivatives |
ES2357992T3 (es) * | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
TW200833328A (en) * | 2006-12-28 | 2008-08-16 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.1.0]hexane derivatives |
CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
MY148544A (en) | 2007-05-23 | 2013-04-30 | Merck Sharp & Dohme | Pyridyl piperidine orexin receptor antagonists |
JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
CA2691373A1 (en) * | 2007-07-03 | 2009-01-08 | Actelion Pharmaceuticals Ltd | 3-aza-bicyclo[3.3.0]octane compounds |
AR067665A1 (es) | 2007-07-27 | 2009-10-21 | Actelion Pharmaceuticals Ltd | Derivados de trans-3- aza-biciclo ( 3.1.0) hexano |
JP2010534646A (ja) * | 2007-07-27 | 2010-11-11 | アクテリオン ファーマシューティカルズ リミテッド | トランス−3−アザ−ビシクロ[3.1.0]ヘキサン誘導体 |
JP2010534647A (ja) * | 2007-07-27 | 2010-11-11 | アクテリオン ファーマシューティカルズ リミテッド | 2−アザ−ビシクロ[3.3.0]オクタン誘導体 |
WO2009040730A2 (en) * | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
CN101903372B (zh) * | 2007-12-21 | 2014-06-18 | 弗·哈夫曼-拉罗切有限公司 | 作为食欲肽受体拮抗剂的杂芳基衍生物 |
NZ588080A (en) | 2008-02-21 | 2012-04-27 | Actelion Pharmaceuticals Ltd | 2-Aza-bicyclo[2.2.1]heptane derivatives |
GB0806536D0 (en) * | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
WO2010038200A1 (en) * | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
EP2358713A1 (de) * | 2008-11-26 | 2011-08-24 | Glaxo Group Limited | Als orexinantagonisten wirkende imidazopyridazinderivate |
MX2011005800A (es) * | 2008-12-02 | 2011-06-20 | Glaxo Group Ltd | Derivados de n{[(1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4. 1.0]hept-4-il]metil}-2-heteroarilamina y sus usos. |
AR074426A1 (es) * | 2008-12-02 | 2011-01-19 | Glaxo Group Ltd | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende |
EP2275421A1 (de) | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro-Amino-Verbindungen geeignet zur Behandlung von unter anderem Schlafstörungen und Drogenabhängigkeit |
JP2013502448A (ja) | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | オレキシンアンタゴニストとして用いられるピペリジン誘導体 |
US20120149723A1 (en) | 2009-08-24 | 2012-06-14 | Romano Di Fabio | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
ES2652662T3 (es) | 2011-02-25 | 2018-02-05 | Merck Sharp & Dohme Corp. | Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
BR112014019426A8 (pt) | 2012-02-07 | 2017-07-11 | Eolas Therapeutics Inc | Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina |
US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
LT2855453T (lt) | 2012-06-04 | 2017-02-27 | Actelion Pharmaceuticals Ltd. | Benzimidazolo prolino dariniai |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
KR102151288B1 (ko) | 2012-10-10 | 2020-09-03 | 이도르시아 파마슈티컬스 리미티드 | [오르토 바이 (헤테로 )아릴]-[2-(메타 바이 (헤테로 )아릴)-피롤리딘-1-일]-메타논 유도체인 오렉신 수용체 안타고니스트 |
MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
NO3077389T3 (de) | 2013-12-03 | 2018-02-10 | ||
PL3077391T3 (pl) | 2013-12-04 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Zastosowanie pochodnych benzimidazoloproliny |
WO2015123355A1 (en) * | 2014-02-12 | 2015-08-20 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
TW201613902A (en) | 2014-08-13 | 2016-04-16 | Eolas Therapeutics Inc | Difluoropyrrolidines as orexin receptor modulators |
WO2016101119A1 (en) | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Fused heteroaryl derivatives as orexin receptor antagonists |
US10894789B2 (en) | 2016-02-12 | 2021-01-19 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
WO2017194548A1 (en) | 2016-05-10 | 2017-11-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
EP3972588A4 (de) * | 2019-06-04 | 2023-05-31 | Hager Biosciences, LLC | Imidazolderivate, zusammensetzungen und verfahren als orexin-antagonisten |
WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60110066T2 (de) * | 2000-06-16 | 2006-02-02 | Smithkline Beecham P.L.C., Brentford | Piperidine zur verwendung als orexinrezeptorantagonisten |
DE60108420T2 (de) * | 2000-11-28 | 2005-12-22 | Smithkline Beecham P.L.C., Brentford | Morpholinderivate als antagonisten an orexinrezeptoren |
US7432270B2 (en) * | 2001-05-05 | 2008-10-07 | Smithkline Beecham P.L.C. | N-aroyl cyclic amines |
GB0130393D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
-
2003
- 2003-09-17 AT AT03797310T patent/ATE344261T1/de not_active IP Right Cessation
- 2003-09-17 US US10/527,833 patent/US20060040937A1/en not_active Abandoned
- 2003-09-17 WO PCT/EP2003/010412 patent/WO2004026866A1/en active IP Right Grant
- 2003-09-17 ES ES03797310T patent/ES2273083T3/es not_active Expired - Lifetime
- 2003-09-17 EP EP03797310A patent/EP1539747B1/de not_active Expired - Lifetime
- 2003-09-17 AU AU2003262516A patent/AU2003262516A1/en not_active Abandoned
- 2003-09-17 JP JP2004537127A patent/JP2006504695A/ja active Pending
- 2003-09-17 DE DE60309481T patent/DE60309481T2/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU2003262516A1 (en) | 2004-04-08 |
DE60309481T2 (de) | 2007-06-21 |
EP1539747B1 (de) | 2006-11-02 |
DE60309481D1 (de) | 2006-12-14 |
ES2273083T3 (es) | 2007-05-01 |
WO2004026866A1 (en) | 2004-04-01 |
US20060040937A1 (en) | 2006-02-23 |
JP2006504695A (ja) | 2006-02-09 |
EP1539747A1 (de) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE344261T1 (de) | Cyclische n-aroylamine als orexinrezeptorantagonisten | |
ATE356818T1 (de) | Verbindungen | |
ATE332300T1 (de) | N-aroyl-(cyclisches amin)-derivate als orexinrezeptor antagonisten | |
ATE405561T1 (de) | Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten | |
ATE312811T1 (de) | Benzamidinderivate als antagonisten von orexinrezeptoren | |
DE60318697D1 (de) | Triazolderivate als tachykininrezeptor-antagonisten | |
ATE461191T1 (de) | N-substituierte 2-oxodihydropyridinderivate als npy antagonisten | |
AU2002341123A1 (en) | N-aroyl cyclic amine derivatives as orexin receptor antagonists | |
ATE286897T1 (de) | Morpholinderivate als antagonisten an orexinrezeptoren | |
ATE500250T1 (de) | Azetidinverbindungen als orexin-rezeptor- antagonisten | |
BRPI0415361A (pt) | antagonistas do receptor muscarìnico de acetilcolina | |
UY3441Q (es) | Cepillo de dientes | |
PT1421075E (pt) | Derivados de piperdina uteis como antagonistas do ccr5 | |
DE602007004999D1 (de) | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten | |
ATE500242T1 (de) | Substituierte 1-piperidin-4-yl-pyrrolidin-3-yl- piperazinderivate und deren verwendung als neurokinin antagonisten | |
DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
DE60238709D1 (de) | 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren | |
BRPI0415281A (pt) | antagonistas de receptor de acetilcolina muscarìnico | |
DE60230491D1 (de) | Als ccr5-antagonisten verwendbare aryloxim-piperazine | |
ATE279923T1 (de) | Urotensin-ii rezeptorantagonisten | |
DE60322237D1 (de) | 6h-thienä2,3-büpyrrolderivate als antagonisten des gonadotropin-freisetzenden hormons (gnrh) | |
ATE504300T1 (de) | Harnstoffderivate als il-8-rezeptorantagonisten | |
ATE390427T1 (de) | Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande | |
UY3444Q (es) | Dentifrico | |
DE60317709D1 (de) | Substituierte 1-piperidin-3-yl-4-piperidin-4-yl-piperazin-derivate und ihre verwendung als neurokinin-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |